Clinical trials sponsored by Peking University Cancer Hospital & Institute

Phase breakdown

Conditions studied

Recruiting trials led by Peking University Cancer Hospital & Institute

• A Biomarker Exploratory Study of Dual Blockade of PD1/PDL1 and CTLA4 and Anti-angiogenic Therapy
  NCT06549907 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Study on the Improvement of Postoperative Symptoms and Survival Benefits of Modified Bufei Decoction in Elderly Patients With Lung Cancer Undergoing Radical Surgery
  NCT06674252 · Phase: Not applicable (e.g. observational or device study) · Ages: 65 Years and older · Sex: All (male and female) · 2 locations
• Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral Melanoma
  NCT05512481 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Camrelizumab in Combination With Apatinib and Temozolomide as First-line Treatment in Advanced Acral Melanoma
  NCT05789043 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Circulating Tumor DNA Guided Adjuvant Chemotherapy for Colon Cancer
  NCT05529615 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Establishment and Clinical Transformation of ADC Drug Efficacy Evaluation System for Breast Cancer Based on Molecular Imaging
  NCT06715020 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Evaluation of Trop-2 ADC in Breast Cancer Patients With Brain Metastases: A Real-World Study
  NCT07251868 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• KN 046 Plus Regorafenib in MSS Metastatic Colorectal Cancer
  NCT05985109 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Organ Preservation First Strategy and Intentional Watch and Wait for MRI Defined Low-risk Rectal Cancer
  NCT06209099 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 85 Years · Sex: All (male and female) · 1 location
• Phase Ib/II Study of Vebreltinib With Furmonertinib in NSCLC Patients With c-Met Amplification After EGFR-TKI Failure
  NCT07087223 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 12 locations
• Prediction of Response to PD-L1 Inhibitor After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer Using Multi-omics-based Liquid Biopsy
  NCT06869239 · Phase: Not specified · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Safety, Efficacy, and Survival Outcomes of Neoadjuvant/Induction Immunotherapy in Surgical and Radiotherapeutic Management of Non-Small Cell Lung Cancer
  NCT06926179 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• Total Neoadjuvant Treatment ±Immunotherapy for High Risk Locally Advanced Rectal Cancer (TNTi)
  NCT06229041 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Trop-2 Targeted PET Probes in Advanced TNBC
  NCT07046455 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location

Common questions

How many trials is Peking University Cancer Hospital & Institute recruiting for?

Peking University Cancer Hospital & Institute is the lead sponsor of 14 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.